未知生产厂商
PF-08046031 (CD228V) is an early clinical-stage antibody-drug conjugate (ADC) targeting CD228 (melanotransferrin), originally developed by Pfizer and licensed to Medicus Pharma under a co-development and license agreement granting Medicus exclusive worldwide rights to the drug.
PF-08046031 (CD228V) is an early clinical-stage antibody-drug conjugate (ADC) targeting CD228 (melanotransferrin), originally developed by Pfizer and licensed to Medicus Pharma under a co-development and license agreement granting Medicus exclusive worldwide rights to the drug.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
